GLP-1 receptor agonists in NAFLD

被引：48
|
作者：
Petit, J. -M. [1 ,2 ]
Verges, B. [1 ,2 ]
机构：
[1] Univ Bourgogne, Ctr Rech, INSERM, LNC UMR1231, Dijon, France
[2] CHU Francois Mitterand, Serv Diabetol & Endocrinol, BP 77908, F-21079 Dijon, France
来源：
DIABETES & METABOLISM | 2017年 / 43卷
关键词：
Steatosis; GLP-1 receptor agonists; type; 2; diabetes; Non-alcoholic fatty liver disease; Fibrosis; GLUCAGON-LIKE PEPTIDE-1; FATTY LIVER-DISEASE; HEPATIC STEATOSIS; NONALCOHOLIC STEATOHEPATITIS; MAGNETIC-RESONANCE; WEIGHT-LOSS; EXENATIDE; LIRAGLUTIDE; OBESITY; ANALOG;
D O I：
10.1016/S1262-3636(17)30070-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：2S28 / 2S33
页数：6
相关论文
共 50 条
  • [1] Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
    Seghieri, Marta
    Christensen, Alexander S.
    Andersen, Andreas
    Solini, Anna
    Knop, Filip K.
    Vilsboll, Tina
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [2] GLP-1 receptor agonists today
    Marre, Michel
    Penfornis, Alfred
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 93 (03) : 317 - 327
  • [3] Emerging GLP-1 receptor agonists
    Lund, Asger
    Knop, Filip K.
    Vilsboll, Tina
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (04) : 607 - 618
  • [4] The Future of the GLP-1 Receptor Agonists
    Hirsch, Irl B.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (15): : 1457 - 1458
  • [5] Positioning on GLP-1 receptor agonists
    Gimenez, Sergio
    Piskorz, Daniel
    Martinez Demaria, Diego
    Nanfara, Silvia
    Lorenzatti, Alberto
    Zapata, Gerardo
    Aguinaga Arrascue, Luis
    Perna, Eduardo
    [J]. REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2021, 50 : 4 - 10
  • [6] The Cardiovascular Effects of GLP-1 Receptor Agonists
    Okerson, Theodore
    Chilton, Robert J.
    [J]. CARDIOVASCULAR THERAPEUTICS, 2012, 30 (03) : e146 - e155
  • [7] GLP-1 receptor agonists in heart failure
    Vaduganathan, Muthiah
    [J]. LANCET, 2024, 404 (10454): : 727 - 729
  • [8] Novel GLP-1 receptor agonists for diabetes
    Garber, Alan J.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (01) : 45 - 57
  • [9] Cardiovascular safety and GLP-1 receptor agonists
    Carty, David M.
    Drummond, Russell
    Fisher, Miles
    [J]. PRACTICAL DIABETES, 2013, 30 (06) : 242 - 245
  • [10] GLP-1 receptor agonists in clinical practice
    Perez, Antonio
    [J]. MEDICINA CLINICA, 2024, 163 (05): : 242 - 244
12345